At FCE Pharma in São Paulo, Gerresheimer will be showcasing a complete solution for packaging effervescent vitamin C tablets, which are currently seeing strong demand. A leading manufacturer of specialty plastic packaging solutions for pharmaceuticals, Gerresheimer is further expanding its newest plant in Anápolis in the Brazilian state of Goiás.
Complete solution for effervescent vitamin C tablets
The packaging solution comprises a small tube made from polypropyl-ene (PP) with capacity for 10 or 16 tablets and a lid made from low-density polyethylene (LDPE) and filled with desiccant. Versions of the lid with or without a flat coil spring are available. The state-of-the-art offset printing press enables the plastic tubes to be printed in up to six colors, while the shock- and waterproof decoration ensures a long useful life. Strong brand identities can thus be shaped in an eye-catching way and in line with corporate design guidelines.
Anápolis plant being expanded
Gerresheimer Anápolis enjoys a favorable strategic location in Goiás state, home to many Latin American generics manufacturers. The factory, which opened its doors last year, is set to house an entire production line for plastic products, assembly and decoration operations, and a logistics center in the future. To this end, the premises are being expanded to over 29,500 square meters this year. The plant will also supply customers all over Brazil with high-quality packaging products and solutions going forward. By the end of 2020, it will be kitted out with machinery capable of manufacturing most products in Gerresheimer’s portfolio for Brazil such as plastic bottles, caps, syringes, beakers, and droppers.
Gerresheimer in Latin America
With its new factory, Gerresheimer now has a presence in two Brazilian states. Alongside Goiás, the company is also represented in the São Paulo region, where several plants provide the full range of pharmaceutical primary packaging made from plastic. Gerresheimer makes insulin pens for the South American market in Indaiatuba, near to the state capital São Paulo. The company also has another factory for plastic products in the Argentinian city of Buenos Aires and manufactures pharmaceutical ampoules and vials from glass in Querétaro, Mexico.
FCE Pharma and the Sindusfarma Award
Gerresheimer will be showcasing its products at booth 037 in hall E at FCE Pharma in the Brazilian city of São Paulo between May 21 and 23 this year. At this trade fair, companies are recognized for their quality with the illustrious Sindusfarma Award. Gerresheimer has won this accolade for exceptional quality no fewer than 19 times in a row. Established in 1933, the Sindusfarma association counts 355 Brazilian and international pharmaceutical companies among its members, representing 95 percent of the country’s pharma market.
Gerresheimer is a leading global partner to the pharma and healthcare industry. With specialty glass and plastic products, the Company contributes to health and well-being. Gerresheimer operates worldwide and its approximately 10,000 employees manufacture products in local markets, close to its customers. With our plants in Europe, America, and Asia, we generate revenues of approximately EUR 1.4 billion. The comprehensive product portfolio includes pharmaceutical packaging and products for the safe, simple administration of medicines: Insulin pens, inhalers, micro pumps, prefillable syringes, injection vials, ampoules, bottles, and containers for liquid and solid medicines with closure and safety systems as well as packaging for the cosmetics industry.
15.05.2019, Gerresheimer AG
Should the content or the design of these sites violate third parties rights or legal prescriptions, we kindly ask you to send us a respective message without invoice or cost. We guarantee that passages where the claim is considered as justified will be removed immediately, without any necessity to involve any lawyer into this issue. We will reject any claim caused by submission of a honorary note in this regard without any prior contact and confirmation of the issueby us and we reserve the right ssue counter claim ourselves because of violation of aforesaid conditions.